|
SLC35B3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.67643676718399E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
5.64326363416967E-12 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
4.702400E-01 |
| Stage1-vs-Stage3 |
2.346600E-01 |
| Stage1-vs-Stage4 |
3.567200E-04 |
| Stage2-vs-Stage3 |
8.851800E-01 |
| Stage2-vs-Stage4 |
7.255700E-02 |
| Stage3-vs-Stage4 |
3.980100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.9380000038669E-08 |
| Normal-vs-Asian |
1.66577862614758E-12 |
| Caucasian-vs-AfricanAmerican |
7.933400E-01 |
| Caucasian-vs-Asian |
7.186000E-01 |
| AfricanAmerican-vs-Asian |
6.234200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.8968828164343E-14 |
| Normal-vs-Female |
1.63258295771129E-12 |
| Male-vs-Female |
2.742800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.7612582199672E-14 |
| Normal-vs-Age(41-60Yrs) |
1.6295853555448E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
9.185600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.435800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.596600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.952200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.416800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.509000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.640620E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.664400E-03 |
| Classical-VS-Follicular |
2.372400E-01 |
| Classical-VS-Other |
7.026200E-01 |
| Classical-VS-Normal |
1.76458847533922E-12 |
| Tall-VS-Follicular |
2.243900E-03 |
| Tall-VS-Other |
6.072800E-01 |
| Tall-VS-Normal |
5.55111512312578E-16 |
| Follicular-VS-Other |
5.119000E-01 |
| Follicular-VS-Normal |
5.37080380169641E-11 |
| Other-VS-Normal |
4.163500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62925228863742E-12 |
| N0-vs-N1 |
1.377780E-01 |
|
|
